New England Biolabs Continues Microbial Fermentation Partnership with ABEC
4.5.2022 16:28:00 EEST | Business Wire | Press release
ABEC, a global provider of engineered solutions and services for biotech manufacturing, today announced it is delivering multiple 40L stainless steel fermenters to New England Biolabs ® (NEB®), further supporting their high-density fermentation of recombinant Escherichia coli and Pichia pastoris. NEB has again selected ABEC based on the recent successful delivery of 400L and 1,000L stainless steel fermenters to their manufacturing facilities in Ipswich and Rowley, MA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005176/en/
The 40L fermenters will replicate the larger scale ABEC fermenters in both design and performance, allowing NEB to conduct multidimensional experimental studies to optimize their fermentation processes. NEB, a global supplier-of-choice for scientific researchers, produces over 500 proteins for research and IVD markets. ABEC’s customized approach and ability to deliver high-quality, reliable fermenters are key to supporting NEB in providing advanced proteins to the scientific community while meeting the highest standards of product quality.
“ABEC’s 40L fermenters will allow New England Biolabs to facilitate a seamless transition from development to production,” said Maurice Southworth, Executive Director of Production at New England Biolabs. “ABEC’s ongoing support enables us to increase our fermentation capabilities as we continue to expand our product offerings into new areas of research.”
“We look forward to continuing our fermentation partnership with New England Biolabs,” said Scott Pickering, ABEC CEO and Chairman. “We appreciate their trust and confidence and remain committed to supporting their success.”
About ABEC
Since 1974, ABEC has been a global leader in delivering engineered process solutions and services for manufacturing in the biotech industry. The majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit abec.com, email info@abec.com and follow us on LinkedIn.
About New England Biolabs
Established in the mid 1970’s, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com. NEB® and NEW ENGLAND BIOLABS® are registered trademarks of New England Biolabs, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005176/en/
Contact information
Media:
Susan Cooper-Curcio, Director of Marketing, +1 (610) 861 4666, scurcio@abec.com
Deana D. Martin, Ph.D. Associate Director, Marketing Communications, +1 (978) 380-7464, martin@neb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. Federal Court Permanently Bans 19 Online Sellers of Fake Urolithin A Supplements and Awards $5.3 Million in Damages to Timeline23.7.2026 17:27:00 EEST | Press release
Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the postbiotic ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted the companies’ motion for default judgments and permanent injunctions against 19 online sellers found to have marketed and sold nutritional supplements falsely advertised as containing Urolithin A. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722951066/en/ Timeline longevity supplement powered by Mitopure; proprietary, highly pure Urolithin A. The order, entered July 15, 2026 by Judge Myong J. Joun in Amazentis SA et al. v. The Partnerships and Unincorporated Associations Identified on Schedule “A”, Case No. 1:25-cv-12913-MJJ (District of Massachusetts), permanently enjoins 19 defaulting defendants from further manufacturing, market
TestMu AI Introduces the Source-to-Verdict Loop in Kane CLI, Carrying Every Requirement to a Ship Decision With Portable Proof23.7.2026 16:45:00 EEST | Press release
TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, introduced a source-to-verdict loop in Kane CLI, its natural-language testing tool. Building on Kane CLI's evolution from a browser automation tool, the loop carries a product requirement to a ship decision, writing the tests, running them in the local browser, collecting the proof, measuring coverage from what actually happened, and returning a verdict. As AI agents write, run, and fix tests, a green checkmark is no longer enough: a step that checks nothing passes, a test written against a spec that changed weeks ago passes, and an agent that says “done” without the click ever landing passes. Empty green and earned green are the same color on every dashboard, the number climbs while the risk does not move. Kane CLI closes that gap: it carries a requirement to a verdict, and proves every step of it. One loop. Source to verdict. You no longer hand Kane CLI a test script, you hand it your
Norway’s health system adopts Wolters Kluwer UpToDate Enterprise Edition23.7.2026 16:30:00 EEST | Press release
Wolters Kluwer Health announced that Norway’s health system has renewed its adoption of UpToDate Enterprise Edition, a market-leading Clinical Decision Support (CDS) solution, for its nationwide health system which includes over 50 public hospitals and 11,000 beds in over 20 trusts. This extends a 15 year partnership with Helsebiblioteket, now part of the Norwegian Institute of Public Health (NIPH). Helping clinicians on a national scale Kjell Tjensvoll, Team Leader for Helsebiblioteket said, ‘‘Providing frontline teams with easy access to the latest medical knowledge is vital in reducing unwarranted variation and improving patient care on a national scale. UpToDate Enterprise Edition enables this, and we are delighted to strengthen our relationship with Wolters Kluwer and provide continued support for clinicians across the country.’’ UpToDate Enterprise Edition was selected by Helsebiblioteket, the Norwegian Electronic Health Library. The selection followed a competitive process by th
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 16:00:00 EEST | Press release
Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilities while strengthening relationships with institutional and private capital partners worldwide. While based in Chicago, John will spend considerable time at the firm’s headquarters in Cleveland as well as in key offices globally. Cr
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 16:00:00 EEST | Press release
Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a lookup often shows who owned a business months or years ago, not who owns it today. Further, ownership chains that cross borders can break entirely onc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom